Evidence map›Paper›PMID 28701189›Full record

ArticleRespiratory research2017

Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia.

Joel Reiter, Shelley Drummond, Ibrahim Sammour, Jian Huang, Victoria Florea, Polliana Dornas, Joshua M Hare, Claudia O Rodrigues, Karen C Young

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Mesenchymal stromal/stem cells and bronchopulmonary dysplasia.Frontiers in cell and developmental biology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Recent research on the mechanism of mesenchymal stem cells in the treatment of bronchopulmonary dysplasia.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Modulation of p75International journal of molecular sciences · 2021
    Article
  18. SDF-1Stem cells international · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Joel ReiterDepartment of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Shelley DrummondDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.
Ibrahim SammourDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.
Jian HuangDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.
Victoria FloreaThe Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Polliana DornasBatchelor Children's Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Joshua M HareDepartment of Medicine/Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, USA.
Claudia O RodriguesDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.
Karen C YoungDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA. Kyoung3@med.miami.edu.ORCID 0000-0002-3921-8467
Children’s Institute · USUniversity of Miami · USHadassah Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) attenuate lung injury in experimental models of bronchopulmonary dysplasia (BPD). Stromal derived factor-1 (SDF-1), a chemokine secreted by MSCs, modulates angiogenesis and stem cell recruitment. Here we tested the hypothesis that SDF-1 mediates MSC protective effects in experimental BPD by modulating angiogenesis.

methodsSDF-1 was knocked down in MSCs using lentiviral vectors carrying anti-SDF-1 short hairpin RNA (MSC-SDF KD). Non-silencing short hairpin RNA was used as control (MSC-NS control). Newborn rats exposed to normoxia or hyperoxia (FiO2 = 0.85) for 3 weeks, were randomly assigned to receive a single intra-tracheal injection (IT) of MSC-NS control or MSC-SDF KD (1 × 10

resultsAdministration of IT MSC-NS control improved lung alveolarization, angiogenesis and inflammation, and attenuated PH in newborn rats with hyperoxia-induced lung injury (HILI). In contrast, knockdown of SDF-1 in MSCs significantly reduced their beneficial effects on alveolarization, angiogenesis, inflammation and PH.

conclusionsThe therapeutic benefits of MSCs in neonatal HILI are in part mediated by SDF-1, through anti-inflammatory and angiogenesis promoting mechanisms. Therapies directly targeting this chemokine may provide a novel strategy for the treatment of BPD.

Indexed as

Mesenchymal Stem Cell TransplantationRegenerationAirway RemodelingAnimalsAnimals, NewbornBronchopulmonary DysplasiaCell ProliferationCells, CulturedChemokine CXCL12Disease Models, AnimalHyperoxiaHypertension, PulmonaryLungMesenchymal Stem CellsNeovascularization, PhysiologicPneumoniaChemokine CXCL12CXCL12 protein, rat

Identifiers

PMID28701189
PMCPMC5506612
OpenAlexW2735433712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.